These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29485063)

  • 1. Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials.
    Vogelius IR; Bentzen SM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):858-865. PubMed ID: 29485063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?
    Vogelius IR; Bentzen SM
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):89-94. PubMed ID: 22652106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
    Miralbell R; Roberts SA; Zubizarreta E; Hendry JH
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e17-24. PubMed ID: 21324610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is alpha/beta for prostate tumors really low?
    Fowler J; Chappell R; Ritter M
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1021-31. PubMed ID: 11429230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer.
    Vogelius IR; Bentzen SM
    Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):299-304. PubMed ID: 31987958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postradiotherapy PSA nadirs fail to support dose escalation study in patients with pretreatment PSA values < 10 ng/ml.
    Herold D; Hanks G; Movsas B; Hanlon A
    Radiat Oncol Investig; 1997; 5(1):15-9. PubMed ID: 9303052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review.
    Brundage M; Lukka H; Crook J; Warde P; Bauman G; Catton C; Markman BR; Charette M;
    Radiother Oncol; 2002 Sep; 64(3):239-50. PubMed ID: 12242112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What hypofractionated protocols should be tested for prostate cancer?
    Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials.
    Stuschke M; Thames HD
    Radiother Oncol; 1999 May; 51(2):113-21. PubMed ID: 10435801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer: Interim Results of a Randomized Trial PCG GU 002.
    Vargas CE; Hartsell WF; Dunn M; Keole SR; Doh L; Eisenbeisz E; Larson GL
    Am J Clin Oncol; 2018 Feb; 41(2):115-120. PubMed ID: 26523442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of heterogeneity in radiosensitivity on LQ based isoeffect formalism for low alpha/beta cancers.
    Moiseenko V
    Acta Oncol; 2004; 43(5):499-502. PubMed ID: 15360056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.
    Wu JS; Wong R; Johnston M; Bezjak A; Whelan T;
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):594-605. PubMed ID: 12573746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets.
    Tamponi M; Gabriele D; Maggio A; Stasi M; Meloni GB; Conti M; Gabriele P
    Br J Radiol; 2019 Jun; 92(1098):20180823. PubMed ID: 31017457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation.
    Zaorsky NG; Palmer JD; Hurwitz MD; Keith SW; Dicker AP; Den RB
    Radiother Oncol; 2015 Jun; 115(3):295-300. PubMed ID: 26028229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AL; Dong L; Kamat A; Pisters L; Kuban DA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):14-9. PubMed ID: 15629589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact.
    Garibaldi E; Gabriele D; Maggio A; Delmastro E; Garibaldi M; Bresciani S; Ortega C; Stasi M; Gabriele P
    Panminerva Med; 2016 Jun; 58(2):121-9. PubMed ID: 26785374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.